Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development.
French drugmaker Sanofi have announced their intentions to collaborate with AI research organisation OpenAi – best known for their AI technologies like Chat GPT – and Formation Bio, a technology company harnessing AI technologies to address supply chain and drug development bottlenecks.
The collaboration will focus on consolidating data and software to develop custom solutions across the drug product lifecycle. A first-of-its-kind collaboration, Sanofi will provide access to proprietary data for the development of AI models. Their aim is to become the first biopharma company powered by AI at scale.
Sanofi CEO Paul Hudson commented “This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its-kind AI model customisations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.”
OpenAI will provide access to their AI capabilities such as fine-tuning AI models and AI expertise. COO Brad Lightcap commented “There is massive potential for AI to accelerate drug development. We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by brining new medicines to market.”
Formation Bio Co-Founder and CEO Benjamine Liu added “I firmly believe that by combining our strengths, Sanofi, OpenAI, and Formation Bio can reimagine drug development in the pharma industry. By creating and implementing customised AI agents and models designed for our industry, companies like Sanofi and Formation Bio can begin to scale with unprecedented productivity and transform the pace at which we bring new medicines to patients.” Formation Bio will provide their own engineering expertise and experience at the intersection of pharmaceuticals and AI. The company operates a tech-driven drug development platform able to deploy AI technologies across various aspects of the pharmaceutical lifecycle.
Source:
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration [Accessed May 22, 2025] https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-21-05-30-00-2885244
Related News
-
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb... -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin... -
News Women in Pharma: Diversi‘tea’ at CPHI North America
CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance